Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs PulteGroup, Inc. (PHM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs PulteGroup, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.93 (market cap $29.60B), while PulteGroup, Inc. trades at $129.4 (market cap $25.22B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and PulteGroup, Inc. pays a 0.79% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | PHM | |
|---|---|---|
Market Cap | $29.60B | $25.22B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $142.56 |
52-Week Low | $205.48 | $110.11 |
Enterprise Value | $27.56B | $25.64B |
Dividend Yield | — | 0.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
PulteGroup (PHM) trades at $129.72, down 0.25% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $137.20. The company reported Q2 2026 earnings of $2.48 per share, beating estimates, but revenue and margins have softened amid housing market pressures. Recent news highlights operational expansion into Northwest Florida and recognition as a Great Place to Work.
The outlook is mixed: strong cash flow, a solid balance sheet, and share buybacks support the stock, but declining net income margins and affordability challenges pose headwinds. With 43% of analysts rating it a buy, the stock offers moderate upside potential balanced against cyclical housing risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →
